Moawia Mohammed Ali Elhassan, Associate Professor at University of Gezira, Consultant of Clinical and Radiation Oncology at Universal Hospital Sudan, shared a post on LinkedIn:
“De-escalating Neoadjuvant Therapy: Results from the Phase III neoCARHP Study in HER2+ Breast Cancer
The phase III neoCARHP trial, recently published in JCO, demonstrates that neoadjuvant taxane plus trastuzumab and pertuzumab, without carboplatin (THP) for six cycles is noninferior to taxane plus trastuzumab and pertuzumab, with carboplatin (TCbHP) in achieving pCR p for stage II-III HER2+ Breast Cancer, with reduced toxicity.
pCR were 64.1% in the THP group and 65.9% in the TCbHP group.
These findings contribute to growing evidence that carboplatin can be safely omitted from neoadjuvant regimens for low – to moderate – risk HER2-positive breast cancer without compromising clinical outcomes.
This “less is more” approach preserves clinical outcomes and improves patient.
Because the study primarily enrolled patients with stage II (>2/3), caution is warranted when applying these results to more advanced cases.”
Title: Neoadjuvant Taxane Plus Trastuzumab and Pertuzumab With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer: The Randomized Noninferiority Phase III neoCARHP Trial
Authors: Hong-Fei Gao, Guo-Lin Ye, Ying Lin, Qin Huang, MM, Jie Dong, MM, Yin Cao, MM, Yan-Xia Zhao, Qian-Jun Chen, Shi-Hui Ma, Jie Ouyang, Jin-Hui Ye, Hua-Wei Yang, Yuan-Qi Zhang, Yong-Cheng Zhang, Gang-Ling Zhang, MM, Wei Li, Yunjian Zhang, Zhi-Yong Wu, Ying-Yi Lin, MM, Teng Zhu, Liu-Lu Zhang, Ci-Qiu Yang, Mei Yang, Hao Peng, Bo Chen, Yi-Tian Chen, Fei Ji, Min-Yi Cheng, Jie-Qing Li, Zefei Jiang, and Kun Wang
Read the Study
More posts featuring Moawia Mohammed Ali Elhassan